Protection against sunburn and skin problems with topical and orally-ingested dosages of zeaxanthin
Zeaxanthin is ingested orally at suitable dosages such as 30 to 100 mg/day for a span of 1 to 2 weeks, can give skin a darker tint that emulates a healthy suntan. In tests involving adults, it was found that zeaxanthin dosages of 30 to about 80 mg per day were sufficient to induce: (i) a mild but noticeable tinting, shading, or darkening of skin color, comparable to a mild suntan; (ii) a substantial increase in the person's ability to withstand elevated levels of sun or UV exposure without any subsequent pain or discomfort, and without the subsequent peeling and flaking that characterizes sunburns; and, (iii) an increased ability of reddened and sunburned skin to convert into intact skin that looks browned and healthily tanned. The topical application of zeaxanthin can further enhance the darkening of the skin.
1. A method of providing a darkened tint to the skin, comprising:
ingesting, over a period of time, at least 10 milligrams per day of zeaxanthin to cause a darkened tint of the skin, the ingested zeaxanthin being in an oral formulation that is one of a group consisting of a capsule, a tablet, and a liquid, the zeaxanthin in the oral formulation being predominantly present in the form of the R-R stereoisomer of zeaxanthin; and
during the period of time, applying a topical formulation to the skin so as to further enhance the darkened tint of the skin, the topical formulation being in the form that is one of a group consisting of a lotion, an ointment, or a cream, the topical formulation including zeaxanthin.
2. The method of claim 1 , wherein the topical formulation includes a permeation-enhancing agent to increase permeation of the zeaxanthin from the topical formulation into epidermal tissue layers of the skin.
3. The method of claim 2 , wherein the permeation-enhancing agent is dimethyl sulfoxide.
4. The method of claim 1 , wherein the period of time is at least 1 week.
5. The method of claim 1 , wherein the zeaxanthin is present in the oral formulation in an oily carrier substance.
6. The method of claim 1 , wherein the oral formulation includes at least one second active agent to induce a darker skin tint in at least some people, the second agent is selected from the group consisting of melanocyte-stimulating hormone and analogs, non-zeaxanthin carotenoids, tyrosine, green tea extract, lutein, lipoic acid, and selenomethionine.
7. The method of claim 6 , wherein the zeaxanthin is the predominate carotenoid in the formulation.
8. The method of claim 6 , wherein the topical formulation further includes at least one of dihydroxyacetone, erythrulose, and tyrosine.
9. The method of claim 1 , wherein the oral formulation provides at least about 20 milligrams per day of zeaxanthin.
10. The method of claim 1 , wherein the zeaxanthin is the predominate carotenoid in the oral formulation.
11. The method of claim 10 , wherein the oral formulation further includes lutein.
12. The method of claim 1 , wherein the ingesting, by itself, causes a darkened skin tint by at least two color shades when measured using a dermatologist skin chart.
13. A method of providing a darkened tint to the skin that emulates a healthy suntan, comprising:
ingesting at least 10 milligrams per day of zeaxanthin, the ingested zeaxanthin being in an oral formulation that is one of a group consisting of a capsule, a tablet, and a liquid, the zeaxanthin in the oral formulation being predominantly present in the form of the R-R stereoisomer of zeaxanthin, the oral formulation further including at least one non-zeaxanthin carotenoid;
after the ingesting, applying a topical formulation to the skin, the topical formulation including zeaxanthin and a permeation-enhancing agent to increase permeation of the zeaxanthin from the topical formulation into the skin; and
after the applying, continuing to ingest at least 10 milligrams per day of zeaxanthin from the oral formulation.
14. The method of claim 13 , wherein the permeation-enhancing agent is dimethyl sulfoxide.
15. The method of claim 13 , wherein the topical formulation further includes at least one of dihydroxyacetone, erythrulose, and tyrosine.
16. The method of claim 13 , wherein the oral formulation provides at least about 20 milligrams per day of zeaxanthin.
17. The method of claim 13 , wherein the ingesting, by itself, causes a darkening of the skin by at least two color shades when measured using a dermatologist skin chart.
18. The method of claim 13 , wherein the zeaxanthin is the predominate carotenoid in the formulation.
19. The method of claim 13 , wherein the (i) ingesting, (ii) applying, and (iii) continuing to apply cause the skin to change to a healthy skin tint that is consistent with a dermatologist color chart.
20. The method of claim 13 , wherein, on the dermatologist color chart, the change to the healthy skin tint is at least two color increments different from the skin tint prior to the (i) ingesting, (ii) applying, and (iii) continuing to apply.
21. The method of claim 13 , wherein the (i) ingesting, (ii) applying, and (iii) continuing to apply helps to reduce the incidence or severity of at least one of an unwanted skin discoloration, a skin irregularity, and a skin inflammation.
22. The method of claim 1 , wherein the (i) ingesting and (ii) applying cause the skin to change to a healthy skin tint that is consistent with a dermatologist color chart.
23. The method of claim 22 , wherein, on the dermatologist color chart, the change to the healthy skin tint is at least two color increments different from the skin tint prior to the (i) ingesting and (ii) applying.
24. The method of claim 1 , wherein the (i) ingesting and (ii) applying helps to reduce the incidence or severity of at least one of an unwanted skin discoloration, a skin irregularity, and a skin inflammation.
25. A method of changing a skin tint to a healthy skin tint, comprising:
ingesting, over a period of time, at least 10 milligrams per day of zeaxanthin, the ingested zeaxanthin being in an oral formulation that is one of a group consisting of a capsule, a tablet, and a liquid, the zeaxanthin in the oral formulation being predominantly present in the form of the R-R stereoisomer of zeaxanthin; and
during the period of time, applying a topical formulation to the skin, the topical formulation being in the form that is one of a group consisting of a lotion, an ointment, or a cream, the topical formulation including zeaxanthin, and
wherein the combination of the ingesting and the applying cause the skin tint to darken to a healthy skin tint that is consistent with a dermatologist color chart.
26. The method of claim 25 , wherein, on the dermatologist color chart, the healthy skin tint is at least two color increments different from the skin tint prior to the (i) ingesting and (ii) applying.